Patents by Inventor Wing Kai CHAN

Wing Kai CHAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancer
    Patent number: 11752139
    Abstract: The present disclosure provides pharmaceutical combinations of orally administered irinotecan and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered irinotecan (e.g., Camptosar®) therapy in a subject suffering from cancer.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: September 12, 2023
    Assignee: Athenex HK Innovative Limited
    Inventors: Min-Fun Rudolf Kwan, E. Douglas Kramer, David Lawrence Cutler, Johnson Yiu-Nam Lau, Wing Kai Chan
  • THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF ANGIOSARCOMA
    Publication number: 20230181566
    Abstract: The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of an angiosarcoma in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol® or paclitaxel formulated with Cremophor®) therapy in a subject suffering from an angiosarcoma.
    Type: Application
    Filed: October 11, 2022
    Publication date: June 15, 2023
    Inventors: Min-Fun Rudolf KWAN, Johnson Yiu-Nam LAU, Wing Kai CHAN, Michael P. SMOLINSKI
  • THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED DOCETAXEL AND A P-GP INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20230046869
    Abstract: The present disclosure provides pharmaceutical combinations of orally administered docetaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered docetaxel (e.g., Taxotere® or docetaxel formulated with polysorbate 80) therapy in a subject suffering from cancer.
    Type: Application
    Filed: June 13, 2022
    Publication date: February 16, 2023
    Inventors: Min-Fun Rudolf KWAN, E. Douglas KRAMER, David Lawrence CUTLER, Johnson Yiu-Nam LAU, Wing Kai CHAN
  • METHODS OF TREATING AND/OR PREVENTING PSORIASIS
    Publication number: 20220305021
    Abstract: The disclosure pertains to methods of treating and/or preventing psoriasis, comprising administering a therapeutically effective amount of KX-01, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
    Type: Application
    Filed: June 5, 2020
    Publication date: September 29, 2022
    Inventors: Johnson Yiu-Nam LAU, Wing Kai CHAN, Min-Fun Rudolf KWAN
  • Therapeutic combinations of orally administered docetaxel and a P-gp inhibitor for the treatment of cancer
    Patent number: 11389442
    Abstract: The present disclosure provides pharmaceutical combinations of orally administered docetaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered docetaxel (e.g., Taxotere® or docetaxel formulated with polysorbate 80) therapy in a subject suffering from cancer.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: July 19, 2022
    Assignee: Athenex HK Innovative Limited
    Inventors: Min-Fun Rudolf Kwan, E. Douglas Kramer, David Lawrence Cutler, Johnson Yiu-Nam Lau, Wing Kai Chan
  • THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED DOCETAXEL AND A P-GP INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20210290614
    Abstract: The present disclosure provides pharmaceutical combinations of orally administered docetaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered docetaxel (e.g., Taxotere® or docetaxel formulated with polysorbate 80) therapy in a subject suffering from cancer.
    Type: Application
    Filed: October 29, 2020
    Publication date: September 23, 2021
    Inventors: Min-Fun Rudolf KWAN, E. Douglas KRAMER, David Lawrence CUTLER, Johnson Yiu-Nam LAU, Wing Kai CHAN
  • Therapeutic combinations of orally administered docetaxel and a P-gp inhibitor for the treatment of cancer
    Patent number: 10849893
    Abstract: The present disclosure provides pharmaceutical combinations of orally administered docetaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered docetaxel (e.g., Taxotere® or docetaxel formulated with polysorbate 80) therapy in a subject suffering from cancer.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: December 1, 2020
    Assignee: Athenex HK Innovative Limited
    Inventors: Min-Fun Rudolf Kwan, E. Douglas Kramer, David Lawrence Cutler, Johnson Yiu-Nam Lau, Wing Kai Chan
  • THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED DOCETAXEL AND A P-GP INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20200188386
    Abstract: The present disclosure provides pharmaceutical combinations of orally administered docetaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered docetaxel (e.g., Taxotere® or docetaxel formulated with polysorbate 80) therapy in a subject suffering from cancer.
    Type: Application
    Filed: December 16, 2019
    Publication date: June 18, 2020
    Inventors: Min-Fun Rudolf KWAN, E. Douglas KRAMER, David Lawrence CUTLER, Johnson Yiu-Nam LAU, Wing Kai CHAN
  • THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED IRINOTECAN AND A P-GP INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20200188363
    Abstract: The present disclosure provides pharmaceutical combinations of orally administered irinotecan and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of cancer in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered irinotecan (e.g., Camptosar®) therapy in a subject suffering from cancer.
    Type: Application
    Filed: December 16, 2019
    Publication date: June 18, 2020
    Inventors: Min-Fun Rudolf KWAN, E. Douglas KRAMER, David Lawrence CUTLER, Johnson Yiu-Nam LAU, Wing Kai CHAN
  • THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF ANGIOSARCOMA
    Publication number: 20190314361
    Abstract: The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of an angiosarcoma in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol® or paclitaxel formulated with Cremophor®) therapy in a subject suffering from an angiosarcoma.
    Type: Application
    Filed: April 12, 2019
    Publication date: October 17, 2019
    Inventors: Min-Fun Rudolf KWAN, Johnson Yiu-Nam LAU, Wing Kai CHAN, Michael P. SMOLINSKI